Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018

被引：0
|
作者：
Mónica Mejía-Ochoa
Paola Andrea Acevedo Toro
Jaiberth Antonio Cardona-Arias
机构：
[1] Laboratorio Médico de referencia,Molecular Hematopathology Research Group, School of Microbiology,University of Antioquia
[2] University of Antioquia,Molecular Hematopathology Research Group, School of Microbiology
[3] Cooperativa Universidad de Colombia,School of Microbiology University of Antioquia, School of Medicine
来源：
BMC Cancer | / 19卷
关键词：
Myeloproliferative disorders; Mutation; Polycythemia vera; Essential thrombocythemia; Primary myelofibrosis; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Pardanani, Animesh D.
    Shah, Neil P.
    Sokol, Lubomir
    Wadleigh, Martha
    Gilliland, D. Gary
    List, Alan F.
    Tefferi, Ayalew
    Kantarjian, Hagop M.
    Bui, Lynne A.
    Clary, Douglas O.
    BLOOD, 2007, 110 (11) : 170A - 170A
  • [32] GERMLINE HOMOZYGOSITY FOR JAK2 46/1 HAPLOTYPE IS A RISK FACTOR OF DEVELOPING PRIMARY OR POST-POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Andrikovics, H.
    Nahajevszky, S.
    Koszarska, M.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Lueff, S.
    Lovas, N.
    Matrai, Z.
    Csomor, J.
    Rasonyi, R.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Kozma, A.
    Adam, E.
    Tordai, A.
    Masszi, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 408 - 408
  • [33] Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review
    Zhao, Long
    Zhang, Hao
    Chen, Juan
    Ma, Haizhen
    Liu, Bei
    HEMATOLOGY, 2024, 29 (01)
  • [34] IMPACT OF JAK2 AND CALR MUTATIONS ON THE DISEASE FEATURES AND OUTCOME AMONG PATIENTS WITH PRIMARY MYELOFIBROSIS OR ESSENTIAL THROMBOCYTHEMIA TREATED WITH STANDARD OF CARE (INCLUDING RUXOLITINIB)
    Hupfer, V.
    Wehrle, J.
    Niemoeller, C.
    Bleul, S.
    Kirchner, C.
    Pfeifer, D.
    Haferlach, T.
    Werner, M.
    Duyster, J.
    von Bubnoff, N.
    Waller, C.
    Pahl, H. L.
    Becker, H.
    HAEMATOLOGICA, 2016, 101 : 562 - 562
  • [35] PROPOSAL FOR A REVISED PROGNOSTIC MODEL IN PRIMARY MYELOFIBROSIS THAT ACCOUNTS FOR JAK2, MPL AND CALR MUTATIONS: AN EXPERIENCE OF A SINGLE CENTER IN CHINA
    Li, B.
    Xu, Z.
    Li, Y.
    Qin, T.
    Zhang, Y.
    Zhang, P.
    Xiao, Z.
    HAEMATOLOGICA, 2016, 101 : 561 - 561
  • [36] Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Santos, Fabio P. S.
    Kantarjian, Hagop M.
    Jain, Nitin
    Manshouri, Taghi
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Kennedy, Debra
    Estrov, Zeev
    Cortes, Jorge
    Verstovsek, Srdan
    BLOOD, 2010, 115 (06) : 1131 - 1136
  • [37] JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
    Maddali, Madhavi
    Kulkarni, Uday Prakash
    Ravindra, Niveditha
    Jajodia, Ekta
    Arunachalam, Arun Kumar
    Suresh, Hemamalini
    Venkatraman, Arvind
    George, Biju
    Mathews, Vikram
    Balasubramanian, Poonkuzhali
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 983 - 989
  • [38] JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
    Madhavi Maddali
    Uday Prakash Kulkarni
    Niveditha Ravindra
    Ekta Jajodia
    Arun Kumar Arunachalam
    Hemamalini Suresh
    Arvind Venkatraman
    Biju George
    Vikram Mathews
    Poonkuzhali Balasubramanian
    Annals of Hematology, 2020, 99 : 983 - 989
  • [39] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
    Shah, Neil P.
    Olszynski, Patrycja
    Sokol, Lubomir
    Verstovsek, Srdan
    Hoffman, Ronald
    List, Alan F.
    Cortes, Jorge
    Kantadian, Hagop M.
    Gilliland, D. Gary
    Clary, Douglas O.
    Bui, Lynne A.
    Wadleigh, Martha
    BLOOD, 2008, 112 (11) : 44 - 44
  • [40] INCIDENCE AND CLINICAL CORRELATION OF CALR MUTATIONS IN PATIENTS WITH JAK2/MPL NEGATIVE ESSENTIAL THROMBOCYTEMIA (ET) AND PRIMARY MYELOFIBROSIS (MF). A SINGLE INSTITUTION COHORT REVIEW.
    Saturnino, H.
    Coucelo, M.
    Mendes, M.
    Ferreira, G.
    Duarte, M.
    Araujo, L.
    Almeida, J.
    Ribeiro, M.
    Celeste, B.
    HAEMATOLOGICA, 2015, 100 : 751 - 752
12345